1 – 15 of 18
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Cell-specific effects in different immune subsets associated with SOCS1 genotypes in multiple sclerosis
(
- Contribution to journal › Article
- 2013
-
Mark
Cerebrospinal fluid oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: Yes.
(
- Contribution to journal › Debate/Note/Editorial
- 2012
-
Mark
Cost of multiple sclerosis in the Czech Republic: The COMS study
(
- Contribution to journal › Article
- 2011
-
Mark
The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: analysis of data from clinical trial and post-marketing surveillance settings.
(
- Contribution to journal › Article
-
Mark
Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a Therapy.
(
- Contribution to journal › Article
-
Mark
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
(
- Contribution to journal › Article
- 2009
-
Mark
Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis
(
- Contribution to journal › Article
-
Mark
Impact of cumulative dose and time on magnetic resonance imaging and clinical outcomes during long-term treatment with subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: exploratory analyses
2009) 25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis In Multiple Sclerosis Journal 15(9). p.126-127(
- Contribution to journal › Published meeting abstract
-
Mark
Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation
2009) 23rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/12th Annual Conference of Rehabilitation in MS 15(2). p.229-237(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions.
(
- Contribution to journal › Article
- 2008
-
Mark
Oral teriflunomide in patients with relapsing multiple sclerosis: baseline clinical features of patients in the TEMSO phase III trial
2008) 13th Annnual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis In Multiple Sclerosis Journal 14. p.85-85(
- Contribution to journal › Published meeting abstract
-
Mark
Nordic trial of methylprednisolone as add-on therapy to interferon-beta for the treatment of relapsing-remitting multiple sclerosis
2008) 13th Annnual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis In Multiple Sclerosis Journal 14. p.299-300(
- Contribution to journal › Published meeting abstract
-
Mark
Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
(
- Contribution to journal › Article
-
Mark
Cognitive dysfunction 24-31 years after isolated optic neuritis.
(
- Contribution to journal › Article
- 2007
-
Mark
A follow-up study of Nordic multiple sclerosis candidate gene regions
(
- Contribution to journal › Article